Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · IEX Real-Time Price · USD
19.52
+0.23 (1.19%)
At close: May 3, 2024, 4:00 PM
19.80
+0.28 (1.43%)
After-hours: May 3, 2024, 4:34 PM EDT
Edgewise Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
88
Market Cap
1.82B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Astrana Health | 1.39B |
Myriad Genetics | 753.20M |
Harmony Biosciences Holdings | 617.51M |
Catalyst Pharmaceuticals | 398.20M |
Beam Therapeutics | 377.71M |
Avadel Pharmaceuticals | 27.96M |
Fusion Pharmaceuticals | 2.07M |
EWTX News
- 11 days ago - Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies - Business Wire
- 19 days ago - Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) - Business Wire
- 5 weeks ago - Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session - Business Wire
- 5 weeks ago - Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 - Business Wire
- 2 months ago - Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 - Business Wire
- 2 months ago - Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference - Business Wire
- 2 months ago - Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - Business Wire
- 2 months ago - Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) - Business Wire